×
About 13,815 results

ALLMedicine™ Alopecia Center

Research & Reviews  3,942 results

Translational impact of omics studies in alopecia areata: recent advances and future pe...
https://doi.org/10.1080/1744666X.2022.2096590
Expert Review of Clinical Immunology; Basmanav FB, Betz RC

Jul 1st, 2022 - Alopecia areata (AA) is a non-scarring, hair loss disorder and a common autoimmune-mediated disease with an estimated lifetime risk of about 2%. To date, the treatment of AA is mainly based on suppression or stimulation of the immune response. Gen...

A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2)
https://clinicaltrials.gov/ct2/show/NCT04797650

Jul 1st, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that s...

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

Jul 1st, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05041803

Jul 1st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Jul 1st, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

see more →

Guidelines  3 results

Guidelines for the diagnosis and treatment of male-pattern and female-pattern hair loss...
https://doi.org/10.1111/1346-8138.14470
The Journal of Dermatology; Manabe M, Tsuboi R et. al.

Jun 5th, 2018 - Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the origi...

Guidelines for management of androgenetic alopecia based on BASP classification--the As...
https://doi.org/10.1111/jdv.12034
Journal of the European Academy of Dermatology and Venere... Lee WS, Lee HJ et. al.

Nov 28th, 2012 - Androgenetic alopecia (AGA), or pattern hair loss, is a common disorder in both Asian men and women. There are several guidelines for the treatment of AGA which are suitable for Caucasian patients; however, each of these has some limitations. Furt...

British Association of Dermatologists' guidelines for the management of alopecia areata...
https://doi.org/10.1111/j.1365-2133.2012.10955.x
The British Journal of Dermatology; Messenger AG, McKillop J et. al.

Apr 25th, 2012 - British Association of Dermatologists' guidelines for the management of alopecia areata 2012.|2012|Messenger AG,McKillop J,Farrant P,McDonagh AJ,Sladden M,|diagnosis,etiology,therapy,methods,therapeutic use,methods,methods,methods,

see more →

Drugs  298 results see all →

Clinicaltrials.gov  427 results

A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA2)
https://clinicaltrials.gov/ct2/show/NCT04797650

Jul 1st, 2022 - This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that s...

A Phase 2 Durability of Response Study of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT04784533

Jul 1st, 2022 - This is a two part, double-blind, randomized, multicenter study to evaluate the regrowth of hair with CTP-543 and subsequent durability of that regrowth following dose reduction in adult patients with moderate to severe alopecia areata.

European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05041803

Jul 1st, 2022 - The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata. Patients from European sites who p...

Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
https://clinicaltrials.gov/ct2/show/NCT05398809

Jul 1st, 2022 - Study Description: This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-wee observation period to asses...

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects
https://clinicaltrials.gov/ct2/show/NCT05380427

Jun 30th, 2022 - To evaluate the safety and tolerability of CU-40101 liniment as a single and multiple topical application in adult male androgenic alopecia subjects; To evaluate the pharmacokinetic (PK) characteristics of CU-40101 liniment administered as a sing...

see more →

News  844 results

Baricitinib's Approval for Alopecia Areata: Considerations for Starting Patients on Treatment
https://www.medscape.com/viewarticle/976527

Jul 1st, 2022 - Dermatologists, who recently celebrated the US Food and Drug Administration's (FDA's) approval of the world's first oral systemic treatment for adults with severe alopecia areata (AA), are now looking ahead to the practicalities of getting the dru...

Best Albuminuria Drug for Diabetes Varies by Patient
https://www.medscape.com/viewarticle/976020

Jun 22nd, 2022 - Dr Viktor R. Curovic A one-size-fits-all approach may not be the best way to treat albuminuria in patients with diabetes. Multiple guidelines recommend a renin-angiotensin system (RAS) inhibitor (an angiotensin-converting enzyme inhibitor or angio...

Hair disorder treatments are evolving
https://www.mdedge.com/dermatology/article/255473/hair-nails/hair-disorder-treatments-are-evolving
Kathleen Doheny

Jun 15th, 2022 - “No matter who the patient is, whether a child, adolescent, or adult, the key to figuring out hair disease is getting a good history,” Maria Hordinsky, MD, professor and chair of the department of dermatology at the University of Minnesota, Minnea.

FDA OKs First Systemic Treatment for Alopecia Areata
https://www.medscape.com/viewarticle/975487

Jun 13th, 2022 - The US Food and Drug Administration (FDA) today approved baricitinib oral tablets as the first systemic treatment for adult patients with severe alopecia areata. The disorder with the hallmark signs of patchy baldness affects more than 300,000 peo...

Atopic dermatitis: Options abound, and more are coming
https://www.mdedge.com/dermatology/article/255353/atopic-dermatitis/atopic-dermatitis-options-abound-and-more-are-coming
Kathleen Doheny

Jun 10th, 2022 - For dermatologists and others treating patients with atopic dermatitis (AD), it is “an incredible time,” Lawrence F. Eichenfield, MD, said at MedscapeLive’s Women’s & Pediatric Dermatology Seminar.

see more →

Patient Education  12 results see all →